MAI Capital Management
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1040197
INDEPENDENCE, OH
Position in ALNY
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$400,021
+$222,272 QoQ
Shares Held
1,209
+170.5% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MAI Capital Management holds $16,329,886 across 273 Biotechnology names. ALNY ranks #8 (2.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
6,357 | $4,911,672 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,218 | $990,425 | |
| 3 | DNLI |
Denali Therapeutics Inc.
|
46,590 | $894,528 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
3,932 | $785,023 | |
| 5 | TRVI |
Trevi Therapeutics, Inc.
|
65,125 | $776,941 | |
| 6 | IBRX |
ImmunityBio, Inc.
|
72,843 | $558,705 | |
| 7 | RPRX |
Royalty Pharma plc
|
8,477 | $406,641 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
1,209 | $400,021 |
All Filings in ALNY
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $400,021 | 1,209 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $177,749 | 447 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $204,744 | 449 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $159,131 | 488 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $120,698 | 447 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $104,477 | 444 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||